Dr. Frederick Lundry Locke, MD

Dr. Locke practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Locke's NPI, 1518129121, was assigned on June 26, 2008. Dr. Locke graduated from Wayne State University School Of Medicine in 2002. Dr. Locke holds Florida license ME108049.

Dr. Locke's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Dr. Locke's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Locke to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Locke practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Locke's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Locke is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Locke's licenses on file in 3 states: Florida, Illinois and Michigan.

Dmand AI lists anemia, chronic anemia, chronic leukemia, multiple myeloma and neutropenia among the conditions Dr. Locke treats.

CMS data shows 30 Medicare services from Dr. Locke across 1 procedure code in 2024, all of them office visits, for 36 Medicare patients. Medicare paid $2,291 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 36 Medicare patients who saw Dr. Locke in 2024. The largest group is 65 to 74, with 17 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 3.97, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Locke's median patient age at 67, with 37% women.

In 2024, Dr. Locke wrote 31 Medicare Part D claims. 100% of them were for generic drugs. CMS names the drug for 14 of them, across 1 drug with 11 or more claims each, at $612 in total drug cost. In 2017, CMS named 97 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Locke for performance year 2024, reported as part of a group. Dr. Locke accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Locke as offering telehealth.

Dmand AI links 223 papers to Dr. Locke, published from 2007 to 2025. 2023 was the busiest year, with 24. The most frequent topics are Immunotherapy, Adoptive, Receptors, Chimeric Antigen and Lymphoma, Large B-Cell, Diffuse. Dr. Locke has published most often in Transplant Cell Ther. Dr. Locke's most frequent co-authors are Taiga Nishihori, MD, Claudio Anasetti, MD and Julio C. Chavez, MD.

Dmand AI links Dr. Locke to 5 clinical trials, 3 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Multiple Myeloma, Blood Protein Disorders and Bronchiolitis Obliterans Syndrome. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 4.

CMS Open Payments shows 131 general payments to Dr. Locke from 18 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 66% of the total. Gilead Sciences, Inc. paid the most, $25,181. It also lists 12 research payments totaling $13,694 from 2019 to 2024.

Dmand AI lists 5 awards for Dr. Locke, most recently Miles for Moffitt Scientist Award in 2015.

Dr. Locke graduated from Wayne State University School Of Medicine in 2002. Dr. Locke is a member of ASBMT, ASCO, ASH and Society for Immunotherapy of Cancer.

Dr. Locke is in network with 8 carriers, including Aetna, United Healthcare and Elevance. HMO plans come from the most carriers, 5. Check the plan with the practice before a visit.